Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma
NCT03241927Phase 2Terminated
- Sponsor
- Nina Bhardwaj
- Start
- Dec 2017
- Primary completion
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in melanoma (2 arms), sponsored by Nina Bhardwaj. Primary endpoints: Percent of LAMP-1 Positive Cells up to 3 years, Percent of Positive Cell for IFN Gamma up to 3 years and 1 more. Started Dec 2017; status: terminated.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03241927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241927.